Opendata, web and dolomites

FuseX

Novel device for simple and effective prevention of post-surgical adhesion build up.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FuseX project word cloud

Explore the words cloud of the FuseX project. It provides you a very rough idea of what is the project "FuseX" about.

killers    multitude    mixture    revolutionary    spain    natural    procedure    hospitals    patients    fusex    pilpel    expenses    pain    additional    chronic    solution    integrate    abdominal    question    anti    biomedical    concentrated    post    found    initial    twice    mix    solidify    adhesion    consequence    innovation    surgery    healthcare    safety    drafted    adhesions    plasma    wound    operations    inflammatories    coagulation    demonstrated    blood    hopes    solutions    saved    antibiotics    efficacy    grow    12    untreated    severity    unnecessary    dr    chain    trials    eio    stress    depending    preliminary    supply    barriers    readmitted    potentially    yair    invasive    infertility    donor    complications    surgical    commercialization    laparoscopic    clinics    putting    initially    schools    35    trauma    device    efficiency    whilst    material    difficulties    pelvic    repeat    size    rapid    translates    function    initiate    plan    strategy    ceo    delivers    market    lithuania    undergo    90    adverse    eliminate   

Project "FuseX" data sheet

The following table provides information about the project.

Coordinator
EIO BIOMEDICAL LTD 

Organization address
address: 13 WADI EL HAJ
city: NAZARETH
postcode: 17111
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.eiobio.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EIO BIOMEDICAL LTD IL (NAZARETH) coordinator 50˙000.00

Map

 Project objective

Surgical adhesions are a consequence of abdominal trauma during surgery. Although there are a multitude of available barriers on the market today, the efficacy of these solutions is still in question and can lead to adverse side effects. If untreated, these surgical adhesions can solidify and grow, potentially leading to infertility, chronic pain, and difficulties in repeat operations. To address adhesions, patients must undergo additional abdominal surgery, putting unnecessary stress on existing healthcare systems. On average, 35% of patients who undergo open abdominal or pelvic surgery are readmitted twice in the following 10 years due to complications. EIO Biomedical has developed a revolutionary anti-adhesion system in order to eliminate initial formation of surgical adhesions. The FuseX system, delivers a mixture of donor blood plasma with a concentrated mix of natural coagulation factors found in the blood. This results in less post-surgical adhesions, and related complications, and translates to an estimated 6-12 B€ in saved expenses per year. Preliminary testing of the material demonstrated a 60-90% reduction of adhesions, depending on the severity, whilst the non-invasive laparoscopic application also reduced open wound size and extent of trauma. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, EIO Biomedical is set to initiate safety and efficiency trials in Lithuania and Spain, where they will initially market their product. After initial testing, device function and efficiency will be further improved to enable a more rapid procedure for scale up to commercialization. Post-commercialization, CEO Dr. Yair Pilpel hopes to integrate anti-inflammatories, pain killers, and antibiotics, into the solution for widespread use in hospitals, clinics, and potentially schools.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUSEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUSEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More